CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Comparative analysis of clinicopathological characteristics and prognosis between E-cadherin-negative breast lymphoepithelioma-like carcinoma and E-cadherin-negative invasive lobular carcinoma.
Comparative analysis of clinicopathological characteristics and prognosis between E-cadherin-negative breast lymphoepithelioma-like carcinoma and E-cadherin-negative invasive lobular carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究结果表明,E-Cad-neg BLEC 是一种以广泛淋巴细胞浸润和高增殖活性为特征的乳腺癌,且与相对较好的预后相关。
E-钙黏蛋白阴性乳腺淋巴上皮瘤样癌(E-Cad-neg BLEC)是一种罕见恶性肿瘤。迄今尚无研究比较E-Cad-neg BLEC与E-钙黏蛋白阴性浸润性小叶癌(ILC)的临床病理特征和预后。
为明确E-Cad-neg BLEC与E-Cad-neg ILC的关系,我们分析了12例E-Cad-neg BLEC患者,并将其临床病理特征和肿瘤预后与578例E-Cad-neg经典型浸润性小叶癌(c-ILC)或43例E-Cad-neg多形性小叶癌(PLC)患者进行比较。
E-Cad-neg BLEC表现为弥漫性、非黏附性肿瘤,呈多形性生长,肿瘤间质内有大量淋巴细胞浸润。5例患者肿瘤周围可见小叶原位癌。与E-Cad-neg c-ILC相比,E-Cad-neg BLEC的ER(p<0.001)、PR(p<0.001)和HER2(p=0.029)表达水平均显著较低,而Ki-67增殖指数较高(p<0.001)。与E-Cad-neg PLC相比,E-Cad-neg BLEC较少出现血管侵犯(p<0.001)和神经周围侵犯(p<0.001),且HER2表达较低(p=0.001)。组织学分子亚型方面,E-Cad-neg BLEC主要为三阴性型,而E-Cad-neg c-ILC和E-Cad-neg PLC主要为Luminal A型和Luminal B型。预后方面,E-Cad-neg BLEC的预后曲线与E-Cad-neg c-ILC接近。TIL(肿瘤浸润淋巴细胞)比例分析显示,E-Cad-neg c-ILC和E-Cad-neg PLC中TIL水平较高均与预后不良相关,与E-Cad-neg BLEC中观察到的良好预后形成对照。
研究结果表明,E-Cad-neg BLEC是一种具有广泛淋巴细胞浸润和高增殖活性的乳腺癌,且与相对良好的预后相关。
E-cadherin-negative breast lymphoepithelial-like carcinoma (E-Cad-neg BLEC) is a rare malignant tumor. To date, no study has compared the clinicopathological characteristics and prognosis between E-Cad-neg BLEC and E-Cad-neg invasive lobular carcinoma (ILC).
To clarify the relationship between E-Cad-neg BLEC and E-Cad-neg ILC, we analyzed 12 patients with E-Cad-neg BLEC, comparing their clinicopathological characteristics and tumor prognosis with those of 578 patients with E-Cad-neg classical invasive lobular carcinoma (c-ILC) or 43 patients with E-Cad-neg pleomorphic lobular carcinoma (PLC).
The results showed that E-Cad-neg BLEC was a diffuse, non-adherent tumor with pleomorphic growth. There was abundant lymphocyte infiltration in the tumor stroma. Lobular carcinoma in situ was observed around the tumor in 5 patients. Compared with E-Cad-neg c-ILC, E-Cad-neg BLEC had significantly lower expression levels of ER (p < 0.001), PR (p < 0.001), and HER2 (p = 0.029), and a higher Ki-67 proliferation index (p < 0.001). Compared with E-Cad-neg PLC, E-Cad-neg BLEC was less likely to exhibit vascular invasion (p < 0.001) and perineural invasion (p < 0.001), and had lower HER2 expression (p = 0.001). In terms of histo-molecular subtypes, E-Cad-neg BLEC was mainly triple-negative, while E-Cad-neg c-ILC and E-Cad-neg PLC were mainly luminal A and luminal B. Regarding prognosis, the prognosis curve of E-Cad-neg BLEC was close to that of E-Cad-neg c-ILC. Analysis of the percentage of tumor-infiltrating lymphocytes (TILs) revealed that in both E-Cad-neg c-ILC and E-Cad-neg PLC, higher TIL levels were associated with a poor prognosis, in contrast to the favorable prognosis observed in E-Cad-neg BLEC.
Our findings indicate that E-Cad-neg BLEC is a type of breast carcinoma characterized by extensive lymphocytic infiltration and high proliferative activity and is associated with a relatively favorable prognosis.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。